JP2024534517A5 - - Google Patents
Info
- Publication number
- JP2024534517A5 JP2024534517A5 JP2024517482A JP2024517482A JP2024534517A5 JP 2024534517 A5 JP2024534517 A5 JP 2024534517A5 JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024534517 A5 JP2024534517 A5 JP 2024534517A5
- Authority
- JP
- Japan
- Prior art keywords
- morphology
- pharmaceutically acceptable
- solvate
- hydrate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246451P | 2021-09-21 | 2021-09-21 | |
| US63/246,451 | 2021-09-21 | ||
| PCT/US2022/044232 WO2023049168A1 (en) | 2021-09-21 | 2022-09-21 | Polymorphs as erbb inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534517A JP2024534517A (ja) | 2024-09-20 |
| JP2024534517A5 true JP2024534517A5 (https=) | 2025-09-30 |
Family
ID=83691602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517482A Pending JP2024534517A (ja) | 2021-09-21 | 2022-09-21 | Ｅｒｂｂ阻害剤としての多形 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425492A1 (https=) |
| EP (1) | EP4405350A1 (https=) |
| JP (1) | JP2024534517A (https=) |
| KR (1) | KR20240099193A9 (https=) |
| CN (1) | CN119110799A (https=) |
| AU (1) | AU2022352658A1 (https=) |
| CA (1) | CA3231697A1 (https=) |
| IL (1) | IL311354A (https=) |
| MX (1) | MX2024003475A (https=) |
| WO (1) | WO2023049168A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN120769850A (zh) * | 2023-03-02 | 2025-10-10 | 江苏康缘药业股份有限公司 | 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用 |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025137424A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Solid forms of an erbb inhibitor |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| US20240075042A1 (en) * | 2020-11-02 | 2024-03-07 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
-
2022
- 2022-09-21 CA CA3231697A patent/CA3231697A1/en active Pending
- 2022-09-21 MX MX2024003475A patent/MX2024003475A/es unknown
- 2022-09-21 AU AU2022352658A patent/AU2022352658A1/en active Pending
- 2022-09-21 CN CN202280075401.6A patent/CN119110799A/zh active Pending
- 2022-09-21 WO PCT/US2022/044232 patent/WO2023049168A1/en not_active Ceased
- 2022-09-21 EP EP22789775.8A patent/EP4405350A1/en active Pending
- 2022-09-21 JP JP2024517482A patent/JP2024534517A/ja active Pending
- 2022-09-21 IL IL311354A patent/IL311354A/en unknown
- 2022-09-21 KR KR1020247013097A patent/KR20240099193A9/ko active Pending
- 2022-09-21 US US18/693,733 patent/US20240425492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534517A5 (https=) | ||
| TWI309647B (https=) | ||
| JP2022186995A5 (https=) | ||
| JP2022049005A5 (https=) | ||
| EP2362873B1 (en) | New crystal form of sunitinib malate | |
| AU2015234328A1 (en) | Calibration marker for 3D printer calibration | |
| KR102142796B1 (ko) | 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도 | |
| CN114437077B (zh) | 用作激酶抑制剂的化合物及其应用 | |
| JP2016528179A5 (https=) | ||
| CN110590749B (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| US8372856B2 (en) | Hydrates of erlotinib hydrochloride | |
| US12390468B2 (en) | Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide | |
| US12187707B2 (en) | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof | |
| EA002836B1 (ru) | Безводные и моногидратные формы n-(3-этинилфениламино)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата | |
| JP2021524835A5 (https=) | ||
| TWI443095B (zh) | 新穎鹽 | |
| TWI705962B (zh) | 喹唑啉衍生物之鹽或其結晶及彼等之製造方法 | |
| JP6928964B2 (ja) | Ｎ−（２−（２−（ジメチルアミノ）エトキシ）−４−メトキシ−５−（（４−（１−メチル−１ｈ−インドール−３−イル）ピリミジン−２−イル）アミノ）フェニル）アクリルアミドの薬学的塩およびそれらの結晶形 | |
| US20150307484A1 (en) | Crystal Form of Dabrafenib and Preparation Method and Use Thereof | |
| JP2022511495A5 (https=) | ||
| TW201008935A (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
| WO2016098070A1 (en) | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine | |
| JP2023548605A5 (https=) | ||
| JP2022530028A5 (https=) | ||
| RU2024110241A (ru) | Конденсированное бицикличное производное, его фармацевтически приемлемые соль, кристаллическая форма и способ их получения |